INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2018

In patients with mild to moderate Alzheimer's disease, low-dose resveratrol with glucose and malate was safe but showed no statistically significant benefits.

Thirty-nine participants with mild to moderate Alzheimer's disease were randomized to receive either an oral preparation containing 5 mg resveratrol, 5 g dextrose, and 5 g malate (RGM) or a matching placebo twice daily with grape juice for 1 year. At 12 months, change scores on the ADAS-cog, MMSE, ADCS-ADL, and NPI showed less deterioration in the treatment group than the control group, but none of these differences reached statistical significance. The intervention was found to be safe and well tolerated, with the most common adverse events being falls (all in the control group and deemed unrelated to the study).

Study type
Randomized, double-blind, placebo-controlled pilot trial
Who was studied
39 subjects screened with mild to moderate Alzheimer's disease
What was measured
Change in ADAS-cog; secondary outcomes included CGIC, MMSE, ADCS-ADL, and NPI

THE PAPER

A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study.

Zhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, Sano M. Alzheimers Dement (N Y), 2018.

PubMed 30480082 ↗DOI 10.1016/j.trci.2018.09.009 ↗

Brain & moodHealthy aging & longevityTop 21: Grapes

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.